Dishman Carbogen Amcis vs Divis Laboratories
Side-by-side stock comparison based on AI earnings call analysis
Which stock has stronger management signals?
Both companies need to be compared on revenue growth quality, margin trajectory and management commentary.
Dishman Carbogen Amcis and Divis Laboratories show active capex signals based on earnings call analysis.
Dishman Carbogen Amcis show fundraising activity or capital structure signals.
| Metric | Dishman Carbogen Amcis | Divis Laboratories |
|---|---|---|
| Current Price | ₹151.06 | ₹9,945.5 |
| Market Cap | ₹2,368.37 Cr. | ₹2.64 L Cr. |
| Industry | Pharmaceuticals & Biotechnology | Pharmaceuticals & Biotechnology |
| P/E Ratio | 130.56 | 88.61 |
| ROE (%) | 1.58 | 16.53 |
| Debt/Equity | 0.46 | — |
| Sales Growth 5Y (%) | 8.93 | 8.67 |
| Profit Growth 5Y (%) | -22.09 | 47.05 |
| Promoter Holding (%) | 59.32 | 51.87 |
| Revenue Rank | Rank 3 | Rank 3 |
| Margin Rank | Rank 3 | Rank 3 |
| Signal | — | — |
| Capex | Yes | Yes |
| Fundraise | Yes | No information |
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.